Breast cancers lacking epidermal growth factor receptor 2 (HER2), estrogen receptor and progesterone receptor, are termed triple-negative breast cancers (TNBC) and are distinguished because of a lack of response to therapies targeting these receptors. This evidence concerns the gene ERBB2 and breast cancer.